copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
About | SynnovationTx We are dedicated to the discovery and development of best-in-class therapeutics that can improve the lives of patients Leveraging our deep expertise in biology and a world class medicinal chemistry team, we are building a diverse pipeline of novel small molecule targeted therapies
Synnovation Therapeutics - LinkedIn Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets
Synnovation Therapeutics - Crunchbase Company Profile Funding Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer
Synnovation Therapeutics Announces Second Program to Enter the Clinic . . . Synnovation is dedicated to the discovery and development of best-in-class therapeutics that can improve the lives of patients Leveraging our deep expertise in biology and a world class medicinal chemistry team, we are building a diverse pipeline of novel small molecule targeted therapies
About - SynnovationTx Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers We are dedicated to the discovery and development of best-in-class and first-in-class therapeutics that can improve the lives of people with cancer
News - SynnovationTx Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors